Medicine and Dentistry
Prostate Cancer
87%
Lutetium 177
80%
Dosimetry
47%
Prostate Specific Membrane Antigen
38%
Radioligand
29%
Positron Emission Tomography-Computed Tomography
28%
Positron Emission Tomography
27%
Absorbed Dose
26%
Neoplasm
25%
Polyethylene Terephthalate
22%
Castration Resistant Prostate Cancer
21%
Fluorine-18
21%
Zirconium 89
19%
Gallium 68
17%
Biochemical Recurrence
15%
Randomized Controlled Trial
13%
Pharmacokinetics
13%
Magnetic Resonance Imaging
13%
Biopsy Technique
11%
Single Photon Emission Computed Tomography-Computed Tomography
10%
Arm
9%
Biodistribution
9%
Metastatic Carcinoma
8%
Salivary Gland
8%
Prostate Specific Antigen
8%
Clinical Study
7%
Recurrent Disease
7%
Progression Free Survival
6%
Single-Photon Emission Computed Tomography
6%
Histopathology
6%
Targeted Radionuclide Therapy
6%
Clinical Dosimetry
6%
Antigen Expression
6%
DNA Repair
6%
Urinary Excretion
6%
Model Selection
6%
Fibroblast
6%
Nephrectomy
6%
Intravesical Drug Administration
6%
Mycobacterium bovis
6%
Cylindroma
5%
Pharmacology, Toxicology and Pharmaceutical Science
Prostate Cancer
100%
Lutetium 177
87%
Prostate Specific Membrane Antigen
52%
Radioligand
47%
Polyethylene Terephthalate
47%
Dosimetry
41%
Neoplasm
27%
Zirconium 89
19%
Gallium 68
17%
Castration Resistant Prostate Cancer
16%
Biochemical Recurrence
15%
Fluorine 18
14%
Randomized Controlled Trial
13%
Pharmacokinetics
13%
Radioisotope
10%
Prostate Specific Antigen
9%
Biodistribution
9%
Salivary Gland Cancer
7%
Retrospective Study
7%
Preclinical Study
7%
Recurrent Disease
7%
Progression Free Survival
6%
Clinical Dosimetry
6%
Solid Malignant Neoplasm
6%
Renal Excretion
6%
Fluciclovine F 18
6%
Antibiotics
6%
Model Selection
6%
Rash
6%
Allergic Reaction
6%
Messenger RNA
6%
Cellulitis
6%
Mycobacterium bovis
6%
Androgen
6%
Diseases
5%
Adenoid Cystic Carcinoma
5%
Salivary Duct Carcinoma
5%
Adverse Event
5%